Study: Spiriva Beats Serevent for COPD Flare-ups
Drug Is More Effective at Preventing Flare-ups of Chronic Pulmonary Obstructive Disease
Personalized Therapy for COPD
Barry Make, MD, a pulmonologist and professor of medicine at National Jewish Health in Denver, says that the new findings may tip the scale toward starting select people with COPD on Spiriva as opposed to other long-acting bronchodilators.
But there is more to it, he says. “I look at each patient as an individual and make treatment decisions based on their particular characteristics and symptoms," he says. “If your goal is to decrease exacerbations in someone who is prone to them, Spiriva may be the right choice. But for someone who doesn’t have so many exacerbations, we may focus on symptoms instead and choose another drug.”
Len Horovitz, MD, an internist and pulmonologist at Lenox Hill Hospital in New York City, says there is more to COPD management than simply increasing time to first exacerbation.
“This is just one parameter,” he says. Others include long-term survival or disease progression and the new study does not look at these.
“It is important to have [Spiriva] on board, but it’s not the only drug that you would want to have on board,” he says.